Scholarlink

<p>Sepsis is characterized by a dysregulated systemic inflammatory response to infection and remains a major global health challenge, underscoring the need for novel therapeutic strategies. Drug repurposing offers a promising strategy, and fluvoxamine (FLV), a selective serotonin reuptake inhibitor (SSRI) widely used in psychiatric treatment, has been reported to exhibit anti-inflammatory properties. Here, we investigated the effects of FLV in a murine model of sepsis induced by cecal ligation and puncture (CLP). Oral pretreatment with FLV for seven days significantly increased the anti-inflammatory cytokine IL-10 in both plasma and peritoneal fluid, without affecting proinflammatory cytokines IL-6 and IL-1β. Conversely, when evaluating the involvement of the central nervous system through intracerebroventricular administration of FLV, a broad reduction in circulating cytokines was observed, encompassing both pro- and anti-inflammatory mediators. In vitro, FLV suppressed inflammatory cytokine production in LPS-stimulated macrophages, indicating a direct effect on immune cells. Notably, these immunomodulatory effects were independent of serotonin signaling and sigma-1 receptor activation, pathways traditionally associated with SSRI mechanisms. We demonstrate that FLV modulates cytokine production through distinct central and peripheral mechanisms. Our findings provide new insights into the immunomodulatory actions of FLV and support its potential repurposing as an adjunctive therapy for inflammatory diseases such as sepsis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Fluvoxamine attenuates inflammation in experimental sepsis via novel non-canonical pathways

  • 期刊论文

  • 发表日期：

    2025年12月15日

查看全文
  • Luis H. A. Costa,
  • Isis P. Trajano,
  • Wanderson S. Santos,
  • Katiuscia M. Araújo,
  • Luiz G. S. Branco

摘要

Sepsis is characterized by a dysregulated systemic inflammatory response to infection and remains a major global health challenge, underscoring the need for novel therapeutic strategies. Drug repurposing offers a promising strategy, and fluvoxamine (FLV), a selective serotonin reuptake inhibitor (SSRI) widely used in psychiatric treatment, has been reported to exhibit anti-inflammatory properties. Here, we investigated the effects of FLV in a murine model of sepsis induced by cecal ligation and puncture (CLP). Oral pretreatment with FLV for seven days significantly increased the anti-inflammatory cytokine IL-10 in both plasma and peritoneal fluid, without affecting proinflammatory cytokines IL-6 and IL-1β. Conversely, when evaluating the involvement of the central nervous system through intracerebroventricular administration of FLV, a broad reduction in circulating cytokines was observed, encompassing both pro- and anti-inflammatory mediators. In vitro, FLV suppressed inflammatory cytokine production in LPS-stimulated macrophages, indicating a direct effect on immune cells. Notably, these immunomodulatory effects were independent of serotonin signaling and sigma-1 receptor activation, pathways traditionally associated with SSRI mechanisms. We demonstrate that FLV modulates cytokine production through distinct central and peripheral mechanisms. Our findings provide new insights into the immunomodulatory actions of FLV and support its potential repurposing as an adjunctive therapy for inflammatory diseases such as sepsis.